AU4556800A - Novel treatment - Google Patents

Novel treatment

Info

Publication number
AU4556800A
AU4556800A AU45568/00A AU4556800A AU4556800A AU 4556800 A AU4556800 A AU 4556800A AU 45568/00 A AU45568/00 A AU 45568/00A AU 4556800 A AU4556800 A AU 4556800A AU 4556800 A AU4556800 A AU 4556800A
Authority
AU
Australia
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45568/00A
Other languages
English (en)
Inventor
Elaine Alison Irving
Andrew A. Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909650.5A external-priority patent/GB9909650D0/en
Priority claimed from GBGB9916655.5A external-priority patent/GB9916655D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4556800A publication Critical patent/AU4556800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU45568/00A 1999-04-27 2000-04-26 Novel treatment Abandoned AU4556800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9909650 1999-04-27
GBGB9909650.5A GB9909650D0 (en) 1999-04-27 1999-04-27 Novel treatment
GBGB9916655.5A GB9916655D0 (en) 1999-07-15 1999-07-15 Novel treatment
GB9916655 1999-07-15
PCT/EP2000/003730 WO2000064422A2 (fr) 1999-04-27 2000-04-26 Nouveau traitement

Publications (1)

Publication Number Publication Date
AU4556800A true AU4556800A (en) 2000-11-10

Family

ID=26315478

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45568/00A Abandoned AU4556800A (en) 1999-04-27 2000-04-26 Novel treatment

Country Status (4)

Country Link
EP (1) EP1173254A2 (fr)
JP (1) JP2002542280A (fr)
AU (1) AU4556800A (fr)
WO (1) WO2000064422A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432699A1 (fr) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurans et pyrroles inhibiteurs de la kinase raf
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2004019873A2 (fr) 2002-08-29 2004-03-11 Scios Inc. Methode pour favoriser l'osteogenese
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
CA2568756A1 (fr) * 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
EP1676574A3 (fr) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Procédé favorisant la survie des tissus ou cellules griffées
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2068414C1 (ru) * 1990-05-10 1996-10-27 Пфайзер Инк. Производные индолона в виде рацемата или оптически активного изомера или их фармацевтически приемлемые аддитивные соли кислоты и кетопроизводные индолона
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
WO1994015645A1 (fr) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation MOLECULES ANTISENS DIRIGEES CONTRE LES GENES DE LA FAMILLE DES ONCOGENES $i(RAF)
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997035855A1 (fr) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement de lesions du systeme nerveux central
AU742696B2 (en) * 1996-11-18 2002-01-10 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use

Also Published As

Publication number Publication date
WO2000064422A3 (fr) 2001-03-01
EP1173254A2 (fr) 2002-01-23
WO2000064422A2 (fr) 2000-11-02
JP2002542280A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
AU2001271434A1 (en) Novel skateboard-bicycle combination
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU5547000A (en) Novel treatment
AU5089400A (en) Arthritis treatment
AU4431000A (en) Novel use
AU5967600A (en) Candystraw
GB9925136D0 (en) Novel treatment
AU4115400A (en) Short-circuiter
PL349347A1 (en) Novel treatment
AU6335000A (en) Depthimeter
AU2023701A (en) Sketcher
AU2804600A (en) Arylaminoalkylamides
AU2699800A (en) Organoceramics
AU6440900A (en) Homogentisate-dioxygenase
AU6098300A (en) Follistatin-3
AU1038501A (en) Novel processes
AU4916900A (en) Benzofuranylsulfonates
AU2359301A (en) Novel ss-defensins
AU7273000A (en) Novel processes
AU4561600A (en) Benzofuranylaminoalcohols
AU4456800A (en) Human hac3
AU1901801A (en) Glucofuranoses
AU4435300A (en) Hula-hoop
AU7303400A (en) Osseo-distractor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase